243 related articles for article (PubMed ID: 31115975)
1. miR-145 inhibits glutamine metabolism through c-myc/GLS1 pathways in ovarian cancer cells.
Li J; Li X; Wu L; Pei M; Li H; Jiang Y
Cell Biol Int; 2019 Aug; 43(8):921-930. PubMed ID: 31115975
[TBL] [Abstract][Full Text] [Related]
2. Long non-coding RNA UCA1 promotes glutamine metabolism by targeting miR-16 in human bladder cancer.
Li HJ; Li X; Pang H; Pan JJ; Xie XJ; Chen W
Jpn J Clin Oncol; 2015 Nov; 45(11):1055-63. PubMed ID: 26373319
[TBL] [Abstract][Full Text] [Related]
3. IGF2BP3 promotes glutamine metabolism of endometriosis by interacting with UCA1 to enhances the mRNA stability of GLS1.
Wang H; Cao Y; Gou Y; Wang H; Liang Z; Wu Q; Tan J; Liu J; Li Z; Cui J; Zhang H; Zhang Z
Mol Med; 2024 May; 30(1):64. PubMed ID: 38760723
[TBL] [Abstract][Full Text] [Related]
4. MicroRNA-376b-3p Suppresses Choroidal Neovascularization by Regulating Glutaminolysis in Endothelial Cells.
Feng Y; Wang L; Dong C; Yang X; Wang J; Zhang X; Yuan Y; Dai J; Huang J; Yuan F
Invest Ophthalmol Vis Sci; 2023 Jan; 64(1):22. PubMed ID: 36719700
[TBL] [Abstract][Full Text] [Related]
5. Dlx-2 and glutaminase upregulate epithelial-mesenchymal transition and glycolytic switch.
Lee SY; Jeon HM; Ju MK; Jeong EK; Kim CH; Park HG; Han SI; Kang HS
Oncotarget; 2016 Feb; 7(7):7925-39. PubMed ID: 26771232
[TBL] [Abstract][Full Text] [Related]
6. Reprogramming of proline and glutamine metabolism contributes to the proliferative and metabolic responses regulated by oncogenic transcription factor c-MYC.
Liu W; Le A; Hancock C; Lane AN; Dang CV; Fan TW; Phang JM
Proc Natl Acad Sci U S A; 2012 Jun; 109(23):8983-8. PubMed ID: 22615405
[TBL] [Abstract][Full Text] [Related]
7. GLS-driven glutamine catabolism contributes to prostate cancer radiosensitivity by regulating the redox state, stemness and ATG5-mediated autophagy.
Mukha A; Kahya U; Linge A; Chen O; Löck S; Lukiyanchuk V; Richter S; Alves TC; Peitzsch M; Telychko V; Skvortsov S; Negro G; Aschenbrenner B; Skvortsova II; Mirtschink P; Lohaus F; Hölscher T; Neubauer H; Rivandi M; Labitzky V; Lange T; Franken A; Behrens B; Stoecklein NH; Toma M; Sommer U; Zschaeck S; Rehm M; Eisenhofer G; Schwager C; Abdollahi A; Groeben C; Kunz-Schughart LA; Baretton GB; Baumann M; Krause M; Peitzsch C; Dubrovska A
Theranostics; 2021; 11(16):7844-7868. PubMed ID: 34335968
[TBL] [Abstract][Full Text] [Related]
8. Myc promotes glutaminolysis in human neuroblastoma through direct activation of glutaminase 2.
Xiao D; Ren P; Su H; Yue M; Xiu R; Hu Y; Liu H; Qing G
Oncotarget; 2015 Dec; 6(38):40655-66. PubMed ID: 26528759
[TBL] [Abstract][Full Text] [Related]
9. Tumor suppressor NDRG2 inhibits glycolysis and glutaminolysis in colorectal cancer cells by repressing c-Myc expression.
Xu X; Li J; Sun X; Guo Y; Chu D; Wei L; Li X; Yang G; Liu X; Yao L; Zhang J; Shen L
Oncotarget; 2015 Sep; 6(28):26161-76. PubMed ID: 26317652
[TBL] [Abstract][Full Text] [Related]
10. Glutaminase 1 plays a key role in the cell growth of fibroblast-like synoviocytes in rheumatoid arthritis.
Takahashi S; Saegusa J; Sendo S; Okano T; Akashi K; Irino Y; Morinobu A
Arthritis Res Ther; 2017 Apr; 19(1):76. PubMed ID: 28399896
[TBL] [Abstract][Full Text] [Related]
11. GLS1 is a protective factor in patients with ovarian clear cell carcinoma and its expression does not correlate with ARID1A-mutated tumors.
Clemente V; Hoshino A; Shetty M; Nelson A; Erickson BK; Baker R; Rubin N; Khalifa M; Weroha SJ; Lou E; Bazzaro M
Cancer Res Commun; 2022 Aug; 2(8):784-794. PubMed ID: 36082022
[TBL] [Abstract][Full Text] [Related]
12. Targeting GLS1 to cancer therapy through glutamine metabolism.
Yu W; Yang X; Zhang Q; Sun L; Yuan S; Xin Y
Clin Transl Oncol; 2021 Nov; 23(11):2253-2268. PubMed ID: 34023970
[TBL] [Abstract][Full Text] [Related]
13. Molecular targeting of glutaminase sensitizes ovarian cancer cells to chemotherapy.
Masamha CP; LaFontaine P
J Cell Biochem; 2018 Jul; 119(7):6136-6145. PubMed ID: 29633308
[TBL] [Abstract][Full Text] [Related]
14. c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism.
Gao P; Tchernyshyov I; Chang TC; Lee YS; Kita K; Ochi T; Zeller KI; De Marzo AM; Van Eyk JE; Mendell JT; Dang CV
Nature; 2009 Apr; 458(7239):762-5. PubMed ID: 19219026
[TBL] [Abstract][Full Text] [Related]
15. Exosomal MiR-381 from M2-polarized macrophages attenuates urethral fibroblasts activation through YAP/GLS1-regulated glutaminolysis.
Chen YH; Xu YC; Lin TT; Chen H; Dong RN; Cai FP; Ke ZB; Chen JY; Wei Y; Zheng QS; Xue XY; Xu N
Inflamm Res; 2023 Jul; 72(7):1359-1373. PubMed ID: 37340070
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of the oxidative stress-induced miR-23a protects the human retinal pigment epithelium (RPE) cells from apoptosis through the upregulation of glutaminase and glutamine uptake.
Li DD; Zhong BW; Zhang HX; Zhou HY; Luo J; Liu Y; Xu GC; Luan CS; Fang J
Mol Biol Rep; 2016 Oct; 43(10):1079-87. PubMed ID: 27411920
[TBL] [Abstract][Full Text] [Related]
17. Blockage of glutaminolysis enhances the sensitivity of ovarian cancer cells to PI3K/mTOR inhibition involvement of STAT3 signaling.
Guo L; Zhou B; Liu Z; Xu Y; Lu H; Xia M; Guo E; Shan W; Chen G; Wang C
Tumour Biol; 2016 Aug; 37(8):11007-15. PubMed ID: 26894601
[TBL] [Abstract][Full Text] [Related]
18. Glutaminase 1 regulates the release of extracellular vesicles during neuroinflammation through key metabolic intermediate alpha-ketoglutarate.
Wu B; Liu J; Zhao R; Li Y; Peer J; Braun AL; Zhao L; Wang Y; Tong Z; Huang Y; Zheng JC
J Neuroinflammation; 2018 Mar; 15(1):79. PubMed ID: 29540215
[TBL] [Abstract][Full Text] [Related]
19. Glutamine metabolism via glutaminase 1 in autosomal-dominant polycystic kidney disease.
Soomro I; Sun Y; Li Z; Diggs L; Hatzivassiliou G; Thomas AG; Rais R; Parker SJ; Slusher BS; Kimmelman AC; Somlo S; Skolnik EY
Nephrol Dial Transplant; 2018 Aug; 33(8):1343-1353. PubMed ID: 29420817
[TBL] [Abstract][Full Text] [Related]
20. The role of GLS1-mediated glutaminolysis/2-HG/H3K4me3 and GSH/ROS signals in Th17 responses counteracted by PPARγ agonists.
Miao Y; Zheng Y; Geng Y; Yang L; Cao N; Dai Y; Wei Z
Theranostics; 2021; 11(9):4531-4548. PubMed ID: 33754076
[No Abstract] [Full Text] [Related]
[Next] [New Search]
